PLEASANT PRAIRIE, Wis. — Eli Lilly and Company has acquired a state-of-the-art injectable medicine manufacturing facility ...

Eli Lilly and Company Stock Down 1.1 % NYSE LLY opened at $902.71 on Friday. Eli Lilly and Company has a 52 week low of $516.57 and a 52 week high of $972.53. The company has a quick ratio of 0.87 ...

Swedbank AB acquired a new position in Eli Lilly and Company during the first quarter worth $932,797,000. Sapient Capital LLC bought a new position in Eli Lilly and Company in the fourth quarter ...

Motley Rice LLC and other lead firms recently convened at the Philadelphia Federal Courthouse during a day-long science-based ...

LLC, founding CEO, Alnylam Pharmaceuticals, Inc. Steve Paul, M.D., former CEO, Karuna Therapeutics, former EVP, Eli Lilly and Company, co-founder and board chair, Rapport Therapeutics and Seaport ...

Recent research highlights the potential of microRNAs as cost-effective and less invasive biomarkers for early diagnosis and ...

OrbiMed Advisors LLC, a prominent investment firm, executed a significant transaction by acquiring an additional 6,807,336 shares of Terns Pharmaceuticals Inc (NASDAQ:TERN). This purchase was made at ...

A probable rate cut has provided hope for the economy. Despite that, the impact on financial markets and stocks remains ...

Two new papers by a team of researchers at Boston University, the Indiana University School of Medicine and the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and the German Center for ...

Lilly has exclusive rights for development and commercialization of EBGLYSS in the U.S. and the rest of the world outside Europe. Lilly's partner Almirall S.A. has licensed the rights to develop and ...

‘Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis’ by William K Karlsson et al. was published in The BMJ ...